US 5766605A
· Sanders
· 1998
[cited by examiner]
US 6063768A
· First
· 2000
[cited by applicant]
US 6139845A
· Donovan
· 2000
[cited by applicant]
US 6143306A
· Donovan
· 2000
[cited by applicant]
US 6261572B1
· Donovan
· 2001
[cited by applicant]
US 6337075B1
· Donovan
· 2002
[cited by applicant]
US 6632440B1
· Quinn et al.
· 2003
[cited by applicant]
US 6977080B1
· Donovan
· 2005
[cited by applicant]
US 7655244B2
· Blumenfeld
· 2010
[cited by applicant]
US 8470337B2
· Manack et al.
· 2013
[cited by applicant]
US 8734810B2
· Blumenfeld
· 2014
[cited by applicant]
US 8747865B2
· Ackerman
· 2014
[cited by applicant]
US 8852163B2
· Deem et al.
· 2014
[cited by applicant]
US 8972004B2
· Simon et al.
· 2015
[cited by applicant]
US 9254314B2
· Finzi et al.
· 2016
[cited by applicant]
US 9707207B2
· Finegold
· 2017
[cited by applicant]
US 20010012828A1
· Aoki et al.
· 2001
[cited by applicant]
US 20070259002A1
· Batchelor
· 2007
[cited by applicant]
US 20090142430A1
· Sanders et al.
· 2009
[cited by applicant]
US 20100303788A1
· Francis et al.
· 2010
[cited by applicant]
US 20120093827A1
· Van Schaack et al.
· 2012
[cited by applicant]
US 20120195878A1
· Haag-Molkenteller et al.
· 2012
[cited by applicant]
US 20120244188A1
· Blumenfeld et al.
· 2012
[cited by applicant]
US 20120251519A1
· Blumenfeld et al.
· 2012
[cited by applicant]
US 20130251830A1
· Manack et al.
· 2013
[cited by applicant]
US 20150086533A1
· Borodic
· 2015
[cited by applicant]
US 20160095908A1
· Borodic et al.
· 2016
[cited by applicant]
US 20170333537A9
· Borodic
· 2017
[cited by applicant]
US 20190300583A1
· Jarpe et al.
· 2019
[cited by applicant]
US 20220143158A1
· Abumrad et al.
· 2022
[cited by applicant]
AU 2013202878
· 2013
[cited by applicant]
EP 2072039
· 2009
[cited by applicant]
JP 2007509953
· 2007
[cited by applicant]
JP 2012107051
· 2012
[cited by applicant]
KR 20100032982
· 2010
[cited by applicant]
KR 20150126979
· 2015
[cited by applicant]
WO 9528171
· 1995
[cited by applicant]
WO 0010598
· 2000
[cited by applicant]
WO 2005072433
· 2005
[cited by applicant]
WO 2010013495
· 2010
[cited by applicant]
WO 2011084507
· 2011
[cited by applicant]
WO 2012134897
· 2012
[cited by applicant]
WO 2014184746
· 2014
[cited by applicant]
WO 2018172264
· 2018
[cited by applicant]
WO 2019126542
· 2019
[cited by applicant]
WO 2019145577
· 2019
[cited by applicant]
WO 2020110458
· 2020
[cited by applicant]
WO 2022183064
· 2022
[cited by applicant]
Duke, Rebecca L; Conley, Stephen F; “Botulinum toxin as treatment for a unique case of subcutaneous emphysema” International Journal of Pediatric Otorhinolaryngology, 71, 353-356, 2007) (Year: 2007).
[cited by examiner]
Voelkel, Norbert F; et al; “COPD/emphysema: The vascular story” Pulmonary Circulation, 1, 320-326. 2011) (Year: 2011).
[cited by examiner]
Vacca et al., “Botulinum toxin A increases analgesic effects of morphine, counters development of morphine tolerance and modulates glia activation and μ opiod receptor expression in neuropathic mice,” Brain, Behavior, a…
[cited by applicant]
Veenstra-Vanderweele et al., “Arbaclofen in Children and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled, Phase 2 Trial,” Neuropsychopharmacology, 42, pp. 1390-1398 (2017).
[cited by applicant]
Wang et al., “Molecular Mechanisms of GLutamate Toxicity in Parkinson's Disease,” Frontiers in Neuroscience, 14:1-12 (2020).
[cited by applicant]
Webmd, “ADHD and Dyslexia: How to Tell Them Apart,” available online at: <https://www.webmd.com/add-adhd/adhd-dyslexia-tell-apart?print=true>, 3 pages (2020).
[cited by applicant]
WebMD, “Treatments for Dyslexia,” available online at: <https://www.webmd.com/children/dyslexia-treatments?print=true>, 1 page (2020).
[cited by applicant]
What-When-How, “Neuroscience,” available online at: <http://what-when-how.com/neuroscience> 2 pages (2020).
[cited by applicant]
Wijesekera and Leigh, “Amyotrophic lateral sclerosis,” Orphanet Journal of Rare Diseases, 4(3), 22 pages (2009).
[cited by applicant]
U.S. Appl. No. 17/880,962, filed Aug. 4, 2022, Botulinum Toxin for Use in Treatment.
[cited by applicant]
U.S. Appl. No. 17/204,922, filed Mar. 17, 2021, Treatment of Dyslexia Using Botulinum Toxin.
[cited by applicant]
U.S. Appl. No. 17/987,549, filed Nov. 15, 2022, Treatment of Asthma Using Botulinihvi Toxin.
[cited by applicant]
U.S. Appl. No. 17/987,653, filed Nov. 15, 2022, Treatment of Cardiac Arrhythmia Using Botulinum Toxin.
[cited by applicant]
U.S. Appl. No. 17/215,082, filed Mar. 29, 2021, Treatment of Amyotrophic Lateral Sclerosis Using Botulinum Toxin.
[cited by applicant]
U.S. Appl. No. 17/987,675, filed Nov. 15, 2022, Treatment of Cirrhosis Using Botulinum Toxin.
[cited by applicant]
U.S. Appl. No. 17/862,282, filed Jul. 11, 2022, Treatment of Diabetes and Chronic Pancreatitis Using Botulinum Toxin.
[cited by applicant]
U.S. Appl. No. 17/862,295, filed Jul. 11, 2022, Treatment of Autism Using Botulinum Toxins.
[cited by applicant]
U.S. Appl. No. 16/657,933, filed Oct. 18, 2019, Treatment of Autism Using Botulinum Toxins.
[cited by applicant]
U.S. Appl. No. 17/525,367, filed Nov. 12, 2021, Botulinum Toxin for Use in Treatment of Autism Spectrum Disorders.
[cited by applicant]
U.S. Appl. No. 16/995,042, filed Aug. 17, 2020, Treatment Methods Using Botulinum Toxins.
[cited by applicant]
U.S. Appl. No. 16/875,912, filed May 15, 2020, Treatment of Dyslexia Using Botulinum Toxin.
[cited by applicant]
U.S. Appl. No. 16/875,924, filed May 15, 2020, Treatment of Asthma Using Botulinum Toxin.
[cited by applicant]
U.S. Appl. No. 16/875,935, filed May 15, 2020, Treatment of Chronic Obstructive Pulmonary Disease Using Botulinum Toxin.
[cited by applicant]
U.S. Appl. No. 16/875,945, filed May 15, 2020, Treatment of Cardiac Arrhythmia Using Botulinum Toxin.
[cited by applicant]
U.S. Appl. No. 16/875,947, filed May 15, 2020, Treatment of Amyotrophic Lateral Sclerosis Using Botulinum Toxin.
[cited by applicant]
U.S. Appl. No. 16/875,951, filed May 15, 2020, Treatment of Cirrhosis Using Botulinum Toxin.
[cited by applicant]
Simpson et al., “Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache,” Neurology, 86(19), pp. 1818-1826 (2016).
[cited by applicant]
Smoot-Reinert et al., “Using Posturography to Examine the Immediate Effects of Vestibular Therapy for Children with Autism Spectrum Disorders: A Feasability Study,” Phys. Occup. Ther. Pediatr., 35(4), pp. 365-380 (2015).
[cited by applicant]
Hiroshi Ueda,“ Lysophosphatidic acid, which is responsible for inducing injury neuropathic pain,” Journal of Japan Pharmacology, vol. 127, Issue 3, pp. 161-165 (2006).
[cited by applicant]
Advance Nursing, “Angle of Injection,” available online at: <https://nursing-skills.blogspot.com/2014/01/angle-of-injection.html>, 2 pages (2020).
[cited by applicant]
Antonucci et al., “SNAP-25 a Known Presynaptic Protein with Emerging Postsynapic Functions,” Frontiers in Synaptic Neuroscience, 9 pages (2016).
[cited by applicant]
Chien et al., “Sympathetic Fiber Sprouting in Chronically Compressed Dorsal Root Ganglia Without Peripheral Axotomy,” Author manuscript, published in final form as: J. Neuropathic Pain Symptom Palliation, 1(1), pp. 19-2…
[cited by applicant]
Children's Hospital of Pittsburgh, “Cirrhosis in Children: Symptoms and Treatment,” available online at: <https://www.chp.edu/our-services/transplanUliver/education/liver-disease-states/cirrhosis>, 4 pages (2020).
[cited by applicant]
Cleveland Clinic, “Glutamate,” 4 pages, retrieved online:https://my.clevelandclinic.org/health/articles/22839-glutamate (2023).
[cited by applicant]
Diel et al., “Photophobia and sensations of dryness in migraine patients occur independent of baseline tear vol. and improve following botulinum toxin A injections,” Author manuscript, published in final form as: Br. J.…
[cited by applicant]
Dobrek and Thor, “Glutamate NMDA Receptors in Pathophysiology and Pharmacotherapy of Selected Nervous System Dseases,” Postepy Hig Med Dosw (online), 65, pp. 338-346 (2011).
[cited by applicant]
Doherty, “The Link Between Migraines and Tinnitus, Buzzing or ringing in your ears could be related to your episodes,” available online at: https://www.verywellhealth.com/link-between-migraines-and-tinnitus-4077631>, 13…
[cited by applicant]
Espinosa-Sanchez and Lopez-Escamez, “New insights into pathophysiology of vestibular migraine,” Frontiers in Neurology, 6(12), pp. 1-6 (2015).
[cited by applicant]
Farnsworth, “What to know about glutamate,” Medical News Today (medicalnewstoday.com), 34 pages (2022).
[cited by applicant]
Fernandez-Rodriguez et al., “Plasma Levels of Substance p. in Liver Cirrhosis: Relationship to the Activation of Vasopressor Systems and Urinary Sodium Excretion,” Hepatology, 21, pp. 35-40 (1995).
[cited by applicant]
Fleischmann et al., “Nitrous oxide may not increase the risk of cancer recurrence after colorectal surgery: a follow-up of a randomized controlled trial,” BMC Anesthesiology, 9 pages (2009).
[cited by applicant]
Glatte et al., “Architecture of the Cutaneous Autonomic Nervous System,” Frontiers in Neurology, 10(970), pp. 1-11 (2019).
[cited by applicant]
Harley Academy, “Understanding Different Types of Botulinum Toxin A,” 5 pages (2021).
[cited by applicant]
Hart et al., “Chronic Pancreatitis: Managing a Difficult Disease,” Am. J. Gastroenterol., 115(1), pp. 49-55 (2020).
[cited by applicant]
Harvard Health Publishing, “Cardiac Arrhythmias, What is it?” available online at: <https://www.health.harvard.edu/a_to_z/cardiac-arrhythmias-a-to-z>, 5 pages (2019).
[cited by applicant]
Herner et al., “Glutamate increases pancreatic cancer cell invasion and migration via AMPA receptor activation and Kras-MAPK signaling,” Int. J. Cancer, 129(10), pp. 2349-2359 (2011).
[cited by applicant]
Hulme and Snowling, “Reading disorders and dyslexia,” Curr. Opin. Pediatr., 28, pp. 731-735 (2016).
[cited by applicant]
Kandel et al., “Principles of Neurai Science,” Third Edition, by Simon & Schuster, p. 218 (1991).
[cited by applicant]
Kumar, “The Emerging Role of Botulinurn Toxin in the Treatment of Orofacial Disorders: Literature Update,” Asian J. Pharm. Clin. Res., 10(9), pp. 21-29 (2017).
[cited by applicant]
LeWitt and Trosch, “Idiosyncratic Adverse Reactions to Intramuscular Botulinum Toxin Type A Injection,” Movement Disorders, 12(6), pp. 1054-1067 (1997).
[cited by applicant]
Lim and Sheet, “Botulinum toxin, Quo Vadis?,” Medical Hypotheses, 69, pp. 718-723 (2007).
[cited by applicant]
Mayo Clinic, “Autism Spectrum Disorder,” available online at: <https://www.mayoclinic.org/diseases-conditions/autism-spectrum-disorder/symptoms-causes/syc-20352928?p=1, 5 pages (2019).
[cited by applicant]
Mayo Clinic, “Epilepsy,” available online at: <https://www.mayoclinic.org/diseases-conditions/epilepsy/diagnosis-treatment/drc-20350098>, 8 pages (2022).
[cited by applicant]
Mazzone and Undem, “Vagal Afferent Innervation of the Airways in Health and Disease,” Physiol. Rev., 96, pp. 975-1024 (2016).
[cited by applicant]
Mitchell and Borasio, “Amyotrophic lateral sclerosis,” Lancet 369, pp. 2031-2041 (2007).
[cited by applicant]
Monroy et al., “The Use of Botulinum Toxin—A in the Treatment of Severe Bruxism in a Patient with Autism: A Case Report,” Special Care in Dentistry, 26(1), pp. 37-39 (2006).
[cited by applicant]
Morin, “Reading skills at different ages,” 3 pages, retrieved Online: https://www.understood.org/en/articles/reading-skills-what-to-expect-at- different-ages (2014).
[cited by applicant]
Mortazavi et al., “Xerostomia Due to Systemic Disease: A Review of 20 Conditions and Mechanisms,” Ann. Med. Health Sci. Res., 4(4), pp. 503-510 (2014).
[cited by applicant]
Nair et al., “Impaired thalamocortical connectivity in autism spectrum disorder: a study of functional and anatomical connectivity,” Brain, A Journal of Neurology, 136, pp. 1942-1955 (2013).
[cited by applicant]
National Institutes of Health, “Juvenile Amyotrophic Lateral Sclerosis,” found online at: <https://rarediseases.info.nih.govtdiseasesi11901/juvenile- amyotrophic-lateral-sclerosis>, 8 pages (2020).
[cited by applicant]
Nemmi et al., “Connectivity of the Human Number Form Area Reveals Development of a Cortical Network for Mathematics,” Front. Hum. Neurosci., 2 pages (2018).
[cited by applicant]
Niebroj-Dobosz and Janik, “Amino acids acting as transmitters in amyotrophic lateral sclerosis (ALS),” Acta Neural. Scand., 100, pp. 6-11 (1999).
[cited by applicant]
Oomens and Forouzanfar, “Pharmaceutical Management of Trigeminal Neuraigia in the Elderly,” Drugs Aging, 32, pp. 717-726 (2015).
[cited by applicant]
Panju et al., “Atypical Sympathetic Arousal In Children with Autism Spectrum Disorder and Its Association with Anxiety Symptomatology,” Molecular Autism, 6(64), 10 pages (2015).
[cited by applicant]
Park and Park, “Botulinum Toxin for the Treatment of Neuropathic Pain,” Toxins, 9(260), 15 pages (2017).
[cited by applicant]
Powell et al., “The Role of CGRP in Tile Development of Morphine Tolerance and Physical Dependence,” 4th International Meeting on Calcitonin Gene-Related Peptide (CGRP), The Scientific World 1(S1), 1 page (2001).
[cited by applicant]
Pugh et al., “Glutamate and choline levels predict individual differences in reading ability in emergent readers,” J. Neurosci., 34(11), pp. 4082-4089 (2014).
[cited by applicant]
Ristic, “7 Proven Roles of Substance P and Its Associated Diseases,” available online at: https://supplements.selfdecode.com/blog/substance-p-roles/>, 9 pages (2021).
[cited by applicant]
Rojas, “The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment,” Author manuscript, published in final form as: J. Neural. Transm., 121(8), pp. 891-905 (2014 ).
[cited by applicant]
Sadick, “Botulinum toxin type B,” (Abstract) Dermatol. Surg., 29(4), pp. 348-350 (2003).
[cited by applicant]
Sarawagi et al., “Glutamate and GABA Homeostasis and Neurometabolism in Major Depressive Disorder,” Frontiers in Psychiatry, 12(637863), pp. 1-16 (2021).
[cited by applicant]
Saunte and Christensen, “Improvement in reading symptoms following botulinum toxin A injection for convergence insufficiency type intermittent exotropia,” Acta Opthalmologica 93(5), pp. e391-e392 (2015).
[cited by applicant]
Scott and Fryer, “Role of Parasympathetic Nerves and Muscarinic Receptors in Allergy and Asthma,” Author manuscript, published in final form as: Chem. Immunol. Allergy, 98, pp. 48-69 (2012).
[cited by applicant]
Shimmura et al., “Alteration of Plasma Glutamate and Glutamine Levels in Children with High-Functioning Autism,” PLoS ONE, 6(10), 6 pages (2011).
[cited by applicant]
Shonkoff JP, Phillips DA, editors “From Neurons to Neighborhoods: The Science of Early Childhood Development,” National Research Council (US) and Institute of Medicine (US) Committee on Integrating the Science of Early …
[cited by applicant]
Smith, “Hyperhidrosis,” Vascular Surgery, 31(5), pp. 251-255 (2015).
[cited by applicant]
Squires et al., “The Use of Botulinum Toxin Injections to Manage Drooling in Amyotrophic Lateral Sclerosis/Motor Neurone Disease: A Systematic Review,” Dysphagia, 29, pp. 500-508 (2014).
[cited by applicant]
Strobl et al., “Best Clinical Practice in Botulinum Toxin Treatment for Children with Cerebral Palsy,” Toxins, 7, pp. 1629-1648 (2015).
[cited by applicant]
Trizna, “Dermatologic Use of Botulinum Toxin,” available online at emedicine.medscape.com; 10 pages (2019).
[cited by applicant]
Alivia Nyhan, “Types of cirrhosis and their causes,” 9 pages (2021).
[cited by applicant]
Avery, “Botulinum Toxin for Atrial Fibrillation? Maybe, But More Study is Needed,” Duke Health, Webpage, Published Nov. 15, 2017, https://corporate.dukehealth.org/news/botulinum-toxin-atrial-fibrillation-maybe-more-stud…
[cited by applicant]
Duke and Conley, “Botulinum toxin as treatment for a unique case of subcutaneous emphysema,” International Journal of Pediatric Otorhinolaryngology, 71, pp. 353-356 (2007).
[cited by applicant]
Gonzalez Eslait et al., “Implementation outcomes of a sensory integration therapy program with computerized dynamic posturography in patients with balance and sensory dysfunction,” J. Otol., 18(1):26-32 (2022).
[cited by applicant]
Kumar et al., “Therapeutic use of Botulinum toxin in pain treatment,” Neuronal Signal, 2(3), 18 pages (2018).
[cited by applicant]
Michaels et al., “Serum Levels of Substance P Are Elevated in Patients With Sickle Cell Disease and Increase Further During Vaso-Occlusive Crisis,” Blood, 92:9, pp. 3148-3151 (1998).
[cited by applicant]
Moyer et al., “Botulinum Toxin Type B: Experimental and ClinicalExperiance,” Therapy with Botulinum Toxin. (Ed) J. Jankovic et al. Marcel Dekker, Inc., New York, pp. 71-85 (1994).
[cited by applicant]
Nockher and Renz, “Neirotrophins and asthma: Novel insight into neuroimmune interaction,” Journal of Allergy and Clinical Immunology, 117(1), pp. 67-71 (2006).
[cited by applicant]
Park et al., “Elevated serum substance P level as a predictive marker for moderately emetognic chemotherapy- induced nausea and vomiting: A prospective cohort study,” Cancer Medicine, 10, pp. 1057-1065 (2021).
[cited by applicant]
Pokushalov et al., “Long-Term Suppression of Atrial Fibrillation by Botulinum Toxin Injection Into Epicardial Fat Pads in Patients Undergoing Cardiac Surgery One-Year Follow-Up of a Randomized Pilot Study,” Circulation:…
[cited by applicant]
Purkiss et al., “A Method for the Measurement of CHI-Glutamate Release from Cultured Dorsal Root Ganglion Neurons,” Biochemical Society Transactions, vol. 26, Article 140, page S108 (1998).
[cited by applicant]
Voelkel et al., “COPD/emphysema: The vascular story,” Pulmonary Circulation, 1, pp. 320-326 (2011).
[cited by applicant]
Zajonc and Roland, “Vetrigo and motion sickness. Part II: Pharmacological treatment,” ENT-Ear, Ear, Nose & Throat Journal, vol. 85, No. 1, pp. 25-35 (2006).
[cited by applicant]